Literature DB >> 21153687

Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.

Miranda P Ween1, Katja Hummitzsch, Raymond J Rodgers, Martin K Oehler, Carmela Ricciardelli.   

Abstract

The assembly of pericellular matrix containing hyaluronan (HA) and versican has been shown to be a pre-requisite for proliferation and migration of mesenchymal cells. In this study, we investigated whether treatment with recombinant versican could induce the formation of a pericellular matrix by ovarian cancer cells (OVCAR-3, OVCAR-5, and SKOV-3) and promote their motility, invasion, and adhesion to peritoneal cells in vitro. We also determined whether versican-induced pericellular matrix formation and metastatic cancer cell behavior could be blocked by small HA oligosaccharides. Only combined treatment with recombinant versican and HA resulted in pericellular matrix formation by OVCAR-5 and SKOV-3 but not by OVCAR-3 cells, which lack the HA receptor, CD44. The motility of OVCAR-5 and SKOV-3 cells was significantly increased in scratch wound and chemotaxis assays following treatment with recombinant versican and HA. Versican and HA also promoted invasion of SKOV-3 and OVCAR-5 cells but had no effect on OVCAR-3 cells. We have demonstrated that exogenous HA significantly increased OVCAR-5 and SKOV-3 adhesion to peritoneal cells but adhesion was not further increased by versican treatment. Small HA oligomers (6-10 disaccharides) were able to significantly block formation of pericellular matrix by OVCAR-5 cells, as well as the increased motility and invasion induced by recombinant versican. HA oligomers also significantly blocked OVCAR-5 adhesion to peritoneal cells both in the presence and absence of exogenous HA. The dependence of CD44 for the versican and HA mediated effects were demonstrated by the inhibition of pericellular matrix formation as well as motility and invasion of OVCAR-5 cells following treatment with CD44 neutralizing antibody in the presence of versican and HA. We conclude that the acquisition of a HA/versican pericellular matrix by ovarian cancer cells increases their metastatic potential. HA oligomers can block this mechanism and are promising inhibitors of ovarian cancer dissemination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153687     DOI: 10.1007/s10585-010-9363-7

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  75 in total

Review 1.  Hyaluronan and homeostasis: a balancing act.

Authors:  Markku I Tammi; Anthony J Day; Eva A Turley
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

Review 2.  Hyaluronan: from extracellular glue to pericellular cue.

Authors:  Bryan P Toole
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

3.  Hyaluronate binding properties of versican.

Authors:  R G LeBaron; D R Zimmermann; E Ruoslahti
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

4.  Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.

Authors:  C Ricciardelli; K Mayne; P J Sykes; W A Raymond; K McCaul; V R Marshall; D J Horsfall
Journal:  Clin Cancer Res       Date:  1998-04       Impact factor: 12.531

5.  Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells.

Authors:  Shibnath Ghatak; Suniti Misra; Bryan P Toole
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

6.  Selective activation of the MEK-ERK pathway is regulated by mechanical stimuli in forming joints and promotes pericellular matrix formation.

Authors:  Edward R Bastow; Katherine J Lamb; Jo C Lewthwaite; Anne C Osborne; Emma Kavanagh; Caroline P D Wheeler-Jones; Andrew A Pitsillides
Journal:  J Biol Chem       Date:  2005-01-12       Impact factor: 5.157

7.  Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.

Authors:  Bryan P Toole
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response.

Authors:  Laura Alaniz; Miguel Rizzo; Mariana Malvicini; Jorge Jaunarena; Diego Avella; Catalina Atorrasagasti; Jorge B Aquino; Mariana Garcia; Pablo Matar; Marcelo Silva; Guilermo Mazzolini
Journal:  Cancer Lett       Date:  2009-01-29       Impact factor: 8.679

9.  Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.

Authors:  Shibnath Ghatak; Suniti Misra; Bryan P Toole
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

10.  Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro.

Authors:  Loraine Heyman; Sabrina Kellouche; Julien Fernandes; Soizic Dutoit; Laurent Poulain; Franck Carreiras
Journal:  Tumour Biol       Date:  2008-09-09
View more
  33 in total

Review 1.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

Review 2.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

3.  Ten-gene biomarker panel: a new hope for ovarian cancer?

Authors:  Dong-Joo Cheon; Sandra Orsulic
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 4.  Charting the unexplored extracellular matrix in cancer.

Authors:  Elysse C Filipe; Jessica L Chitty; Thomas R Cox
Journal:  Int J Exp Pathol       Date:  2018-04-19       Impact factor: 1.925

Review 5.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?

Authors:  Margot Zöller
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

6.  Probing chromatin landscape reveals roles of endocardial TBX20 in septation.

Authors:  Cornelis J Boogerd; Ivy Aneas; Noboru Sakabe; Ralph J Dirschinger; Quen J Cheng; Bin Zhou; Ju Chen; Marcelo A Nobrega; Sylvia M Evans
Journal:  J Clin Invest       Date:  2016-06-27       Impact factor: 14.808

7.  Elevated expression of hyaluronic acid binding protein 1 (HABP1)/P32/C1QBP is a novel indicator for lymph node and peritoneal metastasis of epithelial ovarian cancer patients.

Authors:  Hongyang Yu; Qian Liu; Tao Xin; Lina Xing; Guanglu Dong; Qiuying Jiang; Yanju Lv; Xiaowei Song; Chong Teng; Dayong Huang; Yanju Li; Weixi Shen; Chong Teng; Yinghua Jin; Fubin Zhang
Journal:  Tumour Biol       Date:  2013-08-09

8.  Biosynthesis and expression of a disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats-15: a novel versican-cleaving proteoglycanase.

Authors:  Carolyn M Dancevic; Fiona W Fraser; Adam D Smith; Nicole Stupka; Alister C Ward; Daniel R McCulloch
Journal:  J Biol Chem       Date:  2013-11-12       Impact factor: 5.157

Review 9.  The Many Microenvironments of Ovarian Cancer.

Authors:  Hannah M Micek; Mike R Visetsouk; Andrew J Fleszar; Pamela K Kreeger
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 10.  Targeting hyaluronic acid family for cancer chemoprevention and therapy.

Authors:  Vinata B Lokeshwar; Summan Mirza; Andre Jordan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.